Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulants: A Quick Guide - PubMed
Direct Oral Anticoagulants: A Quick Guide Direct Oral Anticoagulants: A Quick Guide Authors Sikorska Julia 1 , Uprichard James 1 Affiliation 1 The Centre for Haemostasis and Thrombosis, Department of Haematology, St George's Hospital, London, UK. PMID: 30416551 PMCID: PMC6206466 DOI: 10.15420/ecr.2017:11:2
Frontiers | Direct Oral Anticoagulants: From Randomized Clinical Trials
The DOACs act as anticoagulants through the direct inhibition of two different and specific factors on the coagulation pathway, in contrast to the indirect, posttranslational, and wide inhibition by VKAs. Apixaban, rivaroxaban, and edoxaban reversibly inhibit Xa factor, regardless of status (free or in a thrombus).
Frontiers | Cost-Effectiveness Analysis of Direct Oral Anticoagulants
Background: In the clinical setting, the economic benefits of direct oral anticoagulants (DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to estimate and compare the cost-effectiveness of DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) and vitamin K antagonists (VKAs; warfarin) in preventing stroke among AF patients aged >75 years in real-world
- What is a direct oral anticoagulant?
- Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. ...
- When was the first DOAC approved?
- In 2010, the US Food and Drug Administration (FDA) approved its first DOAC, dabigatran, followed by rivaroxaban, apixaban, edoxaban, and betrixaban in the following years.
- Why do clinicians need a DOAC?
- With the expanding role of DOACs, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOACs and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios.
- What are DOACs & how do they work?
- DOACs have revolutionized anticoagulant management and are becoming the cornerstone treatment for stroke prevention in AF and VTE prophylaxis and treatment, and the list of other indications is expanding.
- Are direct oral anticoagulants effective for nonvalvular atrial fibrillation (NVAF)?
- Patients with nonvalvular atrial fibrillation (NVAF) have increased risk of stroke. Emerging direct oral anticoagulants (DOACs) demonstrated better outcomes in the management of NVAF than traditional therapy warfarin. In Hong Kong, the public healthcare system has not yet fully incorporated DOACs into the standard treatment pathway.
- Which DOACs improve QALYs compared to warfarin?
- In base-case results, all DOACs were associated with greater QALYs improvements and lower costs than warfarin. Rivaroxaban, apixaban, dabigatran 150 mg, dabigatran 110 mg, and warfarin resulted in net costs US dollar (USD) 8088, USD 8240, USD 8566, USD 8653, and USD 16 363 and net QALY 5.87, 6.017, 6.022, 5.98, and 5.829, respectively.
